Tech Company Financing Transactions
Nurix Therapeutics Funding Round
Nurix Therapeutics secured a $25.1 million Series B investment round on 5/22/2014. Investors included The Column Group and Third Rock Ventures.
Transaction Overview
Company Name
Announced On
5/22/2014
Transaction Type
Venture Equity
Amount
$25,100,000
Round
Series B
Investors
The Column Group (Timothy Kutzkey)
Third Rock Ventures (Mark Goldsmith)
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
1700 Owens St. 205
San Francisco, CA 94158
USA
San Francisco, CA 94158
USA
Phone
Website
Email Address
Overview
Nurix Therapeutics (Nasdaq: NRIX) is focused on the discovery and development of small molecule inhibitors of ubiquitin ligases to treat a broad range of proliferative and degenerative diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Arthur Sands
Vice President
Jean Chang
Vice President
Cristiana Guiducci
VP - Bus. Development
Pierre Beaurang
VP - Finance
Hans Houte
VP - General Counsel
Christine Ring
VP - R & D
Gwenn Hansen
Browse more venture capital transactions:
Prev: 5/22/2014: true[X] venture capital transaction
Next: 5/22/2014: Assurex Health venture capital transaction
Share this article
News on VC Transactions
We do our best to report on all VC transactions involving tech companies. VC transactions reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs